Evidence map›Paper›PMID 22505850›Full record

ArticlePLoS medicine2012

The imperative to share clinical study reports: recommendations from the Tamiflu experience.

Peter Doshi, Tom Jefferson, Chris Del Mar

Abstract read
In one paragraph

Article in PLoS medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024
    Article
  7. Clinical trial registration and results reporting: a call for transparency, coordination, and meaningful enforcement.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?IIC; international review of industrial property and copyright law · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021
    Article
  18. Article
  19. Optimizing the data available via Health Canada's clinical information portal.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021
    Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Peter DoshiJohns Hopkins University School of Medicine, Baltimore, Maryland, USA. pnd@jhu.edu
Tom Jefferson
Chris Del Mar

Funding

Training in Comparative Effectiveness Research to Improve Family Health ServicesT32HS019488 · AHRQ · JOHNS HOPKINS UNIVERSITY · PI DUGGAN, ANNE K · 2010 to 2010
$866k
AHRQ HHS T32 HS019488AHRQ HHS T32HS019488Department of Health 10/80/01Department of Health HTA/10/80/01
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug IndustryInformation DisseminationOutcome Assessment, Health CareRandomized Controlled Trials as TopicReview Literature as TopicAntiviral AgentsHumansOseltamivirAntiviral AgentsOseltamivir

Identifiers

PMID22505850
PMCPMC3323511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.